Cargando…

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC). Novel predictive markers are required to further improve the selection of patients for this treatment. We assessed the influenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mekenkamp, Leonie JM, Tol, Jolien, Dijkstra, Jeroen R, de Krijger, Inge, Vink-Börger, M Elisa, van Vliet, Shannon, Teerenstra, Steven, Kamping, Eveline, Verwiel, Eugène, Koopman, Miriam, Meijer, Gerrit A, van Krieken, J Han JM, Kuiper, Roland, Punt, Cornelis JA, Nagtegaal, Iris D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508829/ https://www.ncbi.nlm.nih.gov/pubmed/22804917 http://dx.doi.org/10.1186/1471-2407-12-292

Ejemplares similares

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue
por: Tol, Jolien, et al.
Publicado: (2010)

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
por: Knijn, N, et al.
Publicado: (2011)

Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases
por: Mekenkamp, L J M, et al.
Publicado: (2010)

MicroRNA expression in formalin-fixed paraffin embedded tissue using real time quantitative PCR: the strengths and pitfalls
por: Dijkstra, J R, et al.
Publicado: (2012)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
por: Kato, Junko, et al.
Publicado: (2016)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer
por: Simmer, Femke, et al.
Publicado: (2015)

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
por: Kim, Mi-Jung, et al.
Publicado: (2012)

Heterogeneity of KRAS Mutation Status in Rectal Cancer
por: Jo, Peter, et al.
Publicado: (2016)

Targeting GRP78 suppresses oncogenic KRAS protein expression and reduces viability of cancer cells bearing various KRAS mutations
por: Ha, Dat P., et al.
Publicado: (2022)

The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis
por: Cao, De-Dong, et al.
Publicado: (2017)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients
por: Baas, J. M., et al.
Publicado: (2015)

The role of kras mutations and MSI status in diagnosis of colorectal cancer
por: Shemirani, Atena Irani, et al.
Publicado: (2011)

Genetic status of KRAS modulates the role of Neuropilin-1 in tumorigenesis
por: Vivekanandhan, Sneha, et al.
Publicado: (2017)

Genotyping of KRAS Mutational Status by the In-Check Lab-on-Chip Platform
por: Guarnaccia, Maria, et al.
Publicado: (2018)

Characterizing MRI features of rectal cancers with different KRAS status
por: Xu, Yanyan, et al.
Publicado: (2019)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007)

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer
por: Barmettler, Hanna, et al.
Publicado: (2012)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013)

Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma
por: Cheng, Lei, et al.
Publicado: (2015)

KRAS and BRAF mutational status in colon cancer from Albanian patients
por: Martinetti, Daniela, et al.
Publicado: (2014)

The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma
por: Chang, Kuang-Leei, et al.
Publicado: (2016)

Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma
por: Ribeiro, Karen Bento, et al.
Publicado: (2013)

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
por: Radanova, Maria, et al.
Publicado: (2023)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer
por: Park, Hye-Jin, et al.
Publicado: (2017)

Lasting response by vertical inhibition with cetuximab and trametinib in KRAS‐mutated colorectal cancer patient‐derived xenografts
por: Reissig, Timm M., et al.
Publicado: (2023)

Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study
por: Krens, Lisanne L., et al.
Publicado: (2014)

Microarray-based genomic profiling and in situ hybridization on fibrotic bone marrow biopsies for the identification of numerical chromosomal abnormalities in myelodysplastic syndrome
por: Stevens-Kroef, Marian JPL, et al.
Publicado: (2015)

Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy
por: Davies, Janine M, et al.
Publicado: (2011)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
por: Szablewski, Vanessa, et al.
Publicado: (2013)

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status
por: Planck, Maria, et al.
Publicado: (2013)

Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation
por: Huang, Chi-Jung, et al.
Publicado: (2016)

Status of KRAS in iPSCs Impacts upon Self-Renewal and Differentiation Propensity
por: Kubara, Kenji, et al.
Publicado: (2018)

Impact of primary colorectal Cancer location on the KRAS status and its prognostic value
por: Xie, Ming-zhi, et al.
Publicado: (2019)

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
por: Won, Daeyoun David, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cdcg42l5114fu1manuh2h6meg8